Literature DB >> 15465013

Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

Young H Ko1, Barbara L Smith, Yuchuan Wang, Martin G Pomper, David A Rini, Michael S Torbenson, Joanne Hullihen, Peter L Pedersen.   

Abstract

A common feature of many advanced cancers is their enhanced capacity to metabolize glucose to lactic acid. In a challenging study designed to assess whether such cancers can be debilitated, we seeded hepatocellular carcinoma cells expressing the highly glycolytic phenotype into two different locations of young rats. Advanced cancers (2-3cm) developed and were treated with the alkylating agent 3-bromopyruvate, a lactate/pyruvate analog shown here to selectively deplete ATP and induce cell death. In all 19 treated animals advanced cancers were eradicated without apparent toxicity or recurrence. These findings attest to the feasibility of completely destroying advanced, highly glycolytic cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465013     DOI: 10.1016/j.bbrc.2004.09.047

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  138 in total

1.  Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.

Authors:  Susumu Saigusa; Yuji Toiyama; Koji Tanaka; Yoshinaga Okugawa; Hiroyuki Fujikawa; Kohei Matsushita; Keiichi Uchida; Yasuhiro Inoue; Masato Kusunoki
Journal:  Surg Today       Date:  2011-11-11       Impact factor: 2.549

2.  Changing the energy of an immune response.

Authors:  Meghan M Delmastro-Greenwood; Jon D Piganelli
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

3.  Cellular ATP synthesis mediated by type III sodium-dependent phosphate transporter Pit-1 is critical to chondrogenesis.

Authors:  Atsushi Sugita; Shinji Kawai; Tetsuyuki Hayashibara; Atsuo Amano; Takashi Ooshima; Toshimi Michigami; Hideki Yoshikawa; Toshiyuki Yoneda
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

4.  Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells.

Authors:  Lara Macchioni; Magdalena Davidescu; Miriam Sciaccaluga; Cristina Marchetti; Graziella Migliorati; Stefano Coaccioli; Rita Roberti; Lanfranco Corazzi; Emilia Castigli
Journal:  J Bioenerg Biomembr       Date:  2011-07-21       Impact factor: 2.945

5.  The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.

Authors:  Alejandro G Levy; Peter E Zage; Lauren J Akers; Maurizio L Ghisoli; Zhao Chen; Wendy Fang; Sankaranarayanan Kannan; Timothy Graham; Lizhi Zeng; Anna R Franklin; Peng Huang; Patrick A Zweidler-McKay
Journal:  Invest New Drugs       Date:  2010-10-05       Impact factor: 3.850

6.  Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells.

Authors:  Magdalena Davidescu; Miriam Sciaccaluga; Lara Macchioni; Roberto Angelini; Patrizia Lopalco; Maria Grazia Rambotti; Rita Roberti; Angela Corcelli; Emilia Castigli; Lanfranco Corazzi
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

7.  Flow cytometric evaluation of the effects of 3-bromopyruvate (3BP) and dichloracetate (DCA) on THP-1 cells: a multiparameter analysis.

Authors:  Harrie A Verhoeven; Leo J L D van Griensven
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

8.  3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.

Authors:  S M El Sayed; R M Abou El-Magd; Y Shishido; S P Chung; T H Diem; T Sakai; H Watanabe; S Kagami; K Fukui
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

Review 9.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

Review 10.  Heterogeneity of glycolysis in cancers and therapeutic opportunities.

Authors:  Marc O Warmoes; Jason W Locasale
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.